Comparable stake leader
Lantheus Holdings, Inc.
SEC ownership of Perspective Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000728387.
Disclosed value leader
Lantheus Holdings, Inc.
Comparable rows
50/50
Latest evidence
03 Sep 2026
- Public ticker
- CATX on NYSE
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Lantheus Holdings, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Lantheus Holdings, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
03 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000728387
- Issuer location
- Seattle, WA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Perspective Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Lantheus Holdings, Inc.
Disclosed value leader
Lantheus Holdings, Inc.
Comparable rows
50/50
Latest evidence
03 Sep 2026
3/4/5
13D/G
13F
Lead comparable stake: 10%
13D/G row: Lantheus Holdings, Inc.
Showing 1-8 of 50 holder rows.
Quick read
Lantheus Holdings, Inc. leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Lantheus Holdings, Inc.'s linked filing trail.
Comparable ownership
Top 5
Lantheus Holdings, Inc.
10%
Commodore Capital LP
9.9%
TCG Crossover GP II, LLC
6.9%
BlackRock, Inc.
6.8%
Qatar Investment Authority
6.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Lantheus Holdings, Inc. |
3/4/5
13D/G
10%+ Owner
|
10%
from 13D/G
|
$35,479,531
11,273,364 shares
|
-$1,265,350 | 03 Sep 2026 |
| Commodore Capital LP |
13D/G
13F
Company
|
9.9%
|
$29,968,780
11,939,753 shares
|
$0 | 02 Feb 2026 |
| TCG Crossover GP II, LLC |
13D/G
Chen Yu
|
6.9%
|
$21,767,809
7,915,567 shares
|
$0 | 03 Feb 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
6.8%
from 13D/G
|
$32,375,059
9,494,152 shares
|
— | 30 Jun 2026 |
| Qatar Investment Authority |
13D/G
|
6.2%
|
$19,451,597
7,073,308 shares
|
$0 | 04 Feb 2026 |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
Company
|
5.5%
|
$21,413,088
6,316,545 shares
|
+$947,661 | 07 Aug 2026 |
| Avidity Partners Management LP |
13D/G
13F
Company
|
5.3%
|
$29,523,995
6,049,999 shares
|
+$15,659,798 | 20 Feb 2026 |
| STATE STREET CORP |
13F
13D/G
Company · STATE STREET CORPORATION
|
5.3%
from 13D/G
|
$20,636,539
6,051,771 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$2,488,460.
Buys
$42,241
Insiders: 2
Sells
$2,530,701
Insiders: 2
Net
-$2,488,460
Shares: -787,452
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 20,498
Shares: 807,950
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 807,950 | $0 | $2,530,701 | -$2,530,701 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 20,498 | 0 | $42,241 | $0 | +$42,241 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-18 of 18 reporting-owner rows connected to Perspective Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
18
Largest Forms 3/4/5 holder
Lantheus Holdings, Inc.
Net 12M change
-$2,488,459
Latest report
03 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Lantheus Holdings, Inc. | 10%+ Owner | $35,479,531 | -$1,265,350 | -3.4% | Filing P/S | 03 Sep 2026 |
| Lantheus Alpha Therapy, LLC | 10%+ Owner | $35,479,531 | -$1,265,350 | -3.4% | Filing P/S | 03 Sep 2026 |
| Lori A. Woods | Director | $400,989 | Mixed | 02 Mar 2026 | ||
| Robert F. Williamson III | Director | $394,522 | +$19,946 | +5.3% | Mixed | 02 Mar 2026 |
| Johan M. Spoor | Chief Executive Officer, Director | $194,133 | Mixed | 02 Mar 2026 | ||
| Jonathan Robert Hunt | Chief Accounting Officer | $121,202 | +$22,295 | +23% | Filing P/S | 02 Mar 2026 |
| Juan Graham | Chief Financial Officer | $79,490 | Filing P/S | 28 Mar 2025 | ||
| Mark John Austin | VP Finance/Prin Fin&Acct Offic | $30,251 | Mixed | 17 Jul 2024 | ||
| Alan Hoffmann | Director | Mixed | 21 Jul 2022 | |||
| Philip J. Vitale | Director | Mixed | 21 Jul 2022 | |||
| William Cavanagh | Chief R&D Officer | Mixed | 21 Jul 2022 | |||
| Jennifer Streeter | COO & VP of HR | Mixed | 12 Jun 2023 | |||
| Michael W. McCormick | Director | Mixed | 21 Feb 2023 | |||
| Heidi Henson | Director | Mixed | 02 Mar 2026 | |||
| Markus Puhlmann | Chief Medical Officer | Mixed | 02 Mar 2026 | |||
| Joel Sendek | Chief Financial Officer | Mixed | 04 Sep 2025 | |||
| Maria E. Martinez | Director | Mixed | 02 Mar 2026 | |||
| Frank Morich | Director | Mixed | 02 Mar 2026 |
Recent insider transactions for Perspective Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC | CATX | Common Stock | Sale | -1.46% | $526,051 | $3.15 | -167,149 | 11,273,364 | 04 Sep 2026 | Direct |
| Lantheus Alpha Therapy, LLC | CATX | Common Stock | Sale | -1.46% | $526,051 | $3.15 | -167,149 | 11,273,364 | 04 Sep 2026 | Direct |
| Lantheus Alpha Therapy, LLC | CATX | Common Stock | Sale | -0.7% | $250,896 | $3.11 | -80,783 | 11,440,513 | 03 Sep 2026 | Direct |
| Lantheus Alpha Therapy, LLC | CATX | Common Stock | Sale | -0.7% | $250,896 | $3.11 | -80,783 | 11,440,513 | 03 Sep 2026 | Direct |
| Lantheus Alpha Therapy, LLC | CATX | Common Stock | Sale | -0.36% | $131,219 | $3.11 | -42,129 | 11,521,296 | 02 Sep 2026 | Direct |
| Lantheus Alpha Therapy, LLC | CATX | Common Stock | Sale | -0.36% | $131,219 | $3.11 | -42,129 | 11,521,296 | 02 Sep 2026 | Direct |
| Lantheus Alpha Therapy, LLC | CATX | Common Stock | Sale | -0.31% | $111,574 | $3.12 | -35,769 | 11,563,425 | 01 Sep 2026 | Direct |
| Lantheus Holdings, Inc. | CATX | Common Stock | Sale | -0.31% | $111,574 | $3.12 | -35,769 | 11,563,425 | 01 Sep 2026 | Direct |
| Lantheus Alpha Therapy, LLC | CATX | Common Stock | Sale | -0.67% | $245,610 | $3.14 | -78,145 | 11,599,194 | 31 Aug 2026 | Direct |
| Lantheus Holdings, Inc. | CATX | Common Stock | Sale | -0.67% | $245,610 | $3.14 | -78,145 | 11,599,194 | 31 Aug 2026 | Direct |
| Maria E. Martinez | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Frank Morich | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Robert F. Williamson III | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Heidi Henson | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Lori A. Woods | CATX | Stock option (right to buy) | Award | 50,000 | 50,000 | 02 Mar 2026 | Direct | |||
| Johan M. Spoor | CATX | Stock option (right to buy) | Award | 735,000 | 735,000 | 02 Mar 2026 | Direct | |||
| Jonathan Robert Hunt | CATX | Stock option (right to buy) | Award | 90,000 | 90,000 | 02 Mar 2026 | Direct | |||
| Markus Puhlmann | CATX | Stock option (right to buy) | Award | 150,000 | 150,000 | 02 Mar 2026 | Direct | |||
| Jonathan Robert Hunt | CATX | Common Stock | Purchase | 22.5% | $22,295 | $2.03 | 11,000 | 59,800 | 13 Nov 2025 | Direct |
| Robert F. Williamson III | CATX | Common Stock | Purchase | 2595.1% | $19,946 | $2.10 | 9,498 | 9,864 | 12 Nov 2025 | RFW3 Revocable Trust |
* marks a reported price that did not pass the local price check.